Molecular modelling study of the mechanism of high-potency inhibition of human catechol-O-methyltransferase by (-)-epigallocatechin-3-O-gallate

被引:26
|
作者
Zhu, B. T. [1 ]
Shim, J. -Y. [2 ]
Nagai, M. [1 ]
Bai, H. -W. [1 ]
机构
[1] Univ Kansas, Sch Med, Dept Pharmacol Toxicol & Therapeut, Med Ctr, Kansas City, KS 66160 USA
[2] N Carolina Cent Univ, FL Chanbers Biomed Biotechnol Res Inst, Durham, NC USA
关键词
catechol-O-methyltransferase (COMT); methylation; catechol oestrogens; catechol-O-methyltransferase inhibitors; (-)-epigallocatechin-3-O-gallate (EGCG);
D O I
10.1080/00498250701744641
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The molecular mechanism of inhibition of human catechol-O-methyltransferase (COMT) by (-)-epigallocatechin-3-O-gallate (EGCG), which is a modest substrate of COMT but an ultra-potent inhibitor of this enzyme, was studied. EGCG has an IC50 value of 70 nM for inhibiting human liver COMT-mediated O-methylation of 2-hydroxyestradiol, which was 210-760 times more potent than catechin, epigallocatechin and epicatechin. Kinetic analyses showed that EGCG had a strong component of non-competitive inhibition of the O-methylation of 2-hydroxyestradiol. Computational molecular modelling studies showed that the B- and D-rings of EGCG can bind tightly to the human COMT in four different modes (i.e. D-para-OH, D-meta-OH, B-para-OH, and B-meta-OH). The binding geometry of EGCG in these binding modes was found to be less than ideal to form perfect Mg2+ coordination for the catalysis of its own methylation. It is concluded that the very tight binding interaction of EGCG with COMT makes it a potent non-competitive inhibitor, but its imperfect geometry makes it a poor substrate for methylation by this enzyme.
引用
收藏
页码:130 / 146
页数:17
相关论文
共 50 条
  • [1] Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate
    Lu, H
    Meng, XF
    Yang, CS
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) : 572 - 579
  • [2] INHIBITION OF CATECHOL-O-METHYLTRANSFERASE BY N-BUTYL GALLATE
    DORRIS, RL
    DILL, RE
    NEUROPHARMACOLOGY, 1977, 16 (09) : 631 - 634
  • [3] The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo
    Lorenz, Mario
    Paul, Friedemann
    Moobed, Minoo
    Baumann, Gert
    Zimmermann, Benno F.
    Stangl, Karl
    Stangl, Verena
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 : 645 - 651
  • [4] Oligomerization mechanism of epigallocatechin-3-O-gallate during autoxidation
    Matsuo, Yosuke
    Katayama, Kohei
    Yamashita, Takako
    Saito, Yoshinori
    Tanaka, Takashi
    FOOD CHEMISTRY, 2024, 449
  • [5] Green tea extract thermogenesis-induced weight loss by epigallocatechin gallate inhibition of catechol-O-methyltransferase
    Shixian, Q.
    VanCrey, B.
    Shi, J.
    Kakuda, Y.
    Jiang, Y.
    JOURNAL OF MEDICINAL FOOD, 2006, 9 (04) : 451 - 458
  • [6] The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice
    Forester, Sarah C.
    Lambert, Joshua D.
    JOURNAL OF FUNCTIONAL FOODS, 2015, 17 : 183 - 188
  • [7] INHIBITION OF HUMAN LIVER CATECHOL-O-METHYLTRANSFERASE BY FLAVONOIDS
    GUGLER, R
    DENGLER, HJ
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1973, 276 (02) : 223 - 233
  • [8] Oxidative inhibition of human soluble catechol-O-methyltransferase
    Cotton, NJH
    Stoddard, B
    Parson, WW
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (22) : 23710 - 23718
  • [9] Impulsivity and Catechol-O-Methyltransferase Inhibition: A Translational Study
    Kayser, Andrew
    Allen, Daicia
    Navarro-Cebrian, Ana
    Mitchell, Jennifer
    Fields, Howard
    NEUROLOGY, 2012, 78
  • [10] Hibernation, reversible cell growth inhibition by epigallocatechin-3-O-gallate
    Matsumura, Kazuaki
    Kim, Jong-Yoon
    Tsutsumi, Sadami
    Hyon, Suong-Hyu
    JOURNAL OF BIOTECHNOLOGY, 2007, 127 (04) : 758 - 764